<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03015090</url>
  </required_header>
  <id_info>
    <org_study_id>2016D01C013</org_study_id>
    <nct_id>NCT03015090</nct_id>
  </id_info>
  <brief_title>Association Study Between CYP1A2 Gene Polymorphisms and Metabolism of Theophylline</brief_title>
  <official_title>Association Study Between CYP1A2 Gene Polymorphisms and Metabolism of Theophylline in Han and Uygur Patients With COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>XiaoGuang Zou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Southern Medical University, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kashgar 1st People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine whether common CYP1A2 gene polymorphisms effect
      metabolism of theophylline in Han and Uygur Patients with chronic obstructive pulmonary
      disease patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentrations of theophylline</measure>
    <time_frame>one week</time_frame>
    <description>Blood samples will be taken after receiving oral theophylline</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>theophylline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Theophylline</intervention_name>
    <description>After oral theophylline 200mg per day for one week, blood sample will be collected for determining plasma concentrations of theophylline and it's metabolites and the genotypes of CYP1A2</description>
    <arm_group_label>theophylline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18-75 years,Weight 40-80kg COPD patients, male or female; regularly visiting our
             hospital; taking a sustained-release preparation of theophylline continuously for at
             least 2 weeks

        Exclusion Criteria:

          -  Patients with renal or hepatic dysfunction; Patients with congestive heart failure;
             Patients with hypothyroidism or hyperthyroidism; Patients currently taking drugs
             likely to effect theophylline metabolism or who had taken such drugs in the preceding
             week; Patients with extreme obesity Patients with very severe Chronic Obstructive
             Pulmonary Disease(COPD)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaoguang Zou</last_name>
    <phone>+86-09982962533</phone>
    <email>zxgksrmyy@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hanzohra Upur</last_name>
    <phone>+86-18699822959</phone>
    <email>hanzuola@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kashgar 1st People's Hospital</name>
      <address>
        <city>Kashgar</city>
        <state>Xinjiang</state>
        <zip>844000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanzohra Upur, Master</last_name>
      <phone>+86-18699822959</phone>
      <email>hanzuola@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2017</study_first_submitted>
  <study_first_submitted_qc>January 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2017</study_first_posted>
  <last_update_submitted>January 5, 2017</last_update_submitted>
  <last_update_submitted_qc>January 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Kashgar 1st People's Hospital</investigator_affiliation>
    <investigator_full_name>XiaoGuang Zou</investigator_full_name>
    <investigator_title>Professor of Pharmacy</investigator_title>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>CYP1A2</keyword>
  <keyword>Theophylline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Theophylline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

